IFNA1 and colorectal carcinoma: These data support the hypothesis that in our experimental setting the continuous IFNα administration has no direct antiproliferative activity towards CRC cells consistent with our previous reported data (Figure 4—figure supplement 1A-C; Catarinella et al., 2016).